Abstract 135P
Background
c-Ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement are found in 1-2% of non-small cell lung cancers (NSCLC). More than 30 different fusion partner genes of ROS1 in NSCLC have been reported and most of these ROS1 fusions respond well to crizotinib, entrectinib, ceritinib and lorlatinib. With the development of next-generation sequencing (NGS), more novel partners for ROS1 rearrangement have been identified. Here, we aimed to report the landscape of ROS1 rearrangement in Chinese patients with solid tumors.
Methods
Tissue or blood samples were subjected to NGS in a College of American Pathologists-certified and Clinical Laboratory Improvement Amendments-accredited lab for ROS1 arrangement.
Results
In total, we profiled more than 40,000 patients, among which 92 cases with 24 ROS1 fusion partner, harboring 10 reported partners and 14 novel partners. The average ROS1 rearrangement patients' age was 57 years (range, 16-82 years). Among all the ROS1 fusion cases (n=92), lung cancer were the largest proportion with 89.1% (n=82), retroperitoneal neoplasm and gastric cancer accounted for 2.2% (n=2), and there was one case in colorectal cancer, liver cancer, liposarcoma, schwannoma, epithelioid hemangioendothelioma and squamous cell carcinoma of the floor of the mouth respectively. The most common reported ROS1 fusion partners were CD74 (n=35), EZR (n=18) and SDC4 (n=11). In 16 cases, 14 novel ROS1 fusion partners were discovered, the novel DCBLD1-ROS1 occurred three times in 3 lung cancer patients. There were two special lung cancer cases with two ROS1 fusions. One case detected the reported CD74-ROS1 fusion and reported SLC34A2-ROS1 fusion, the other case detected novel DCBLD1-ROS1 fusion and reported GOPC-ROS1 fusion.
Conclusions
Novel ROS1 fusions are detected in patients with not only NSCLC but also other solid tumors. NGS fusion assay is an optional method for screening novel fusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.